Changing the Future of Allogenic Engineered T-cell Therapy
Through its groundbreaking ProTcell™ platform, Smart Immune has developed clinical stage T-cell progenitor-based cell and gene therapy to rapidly and fully reset patients’ immune systems to fight cancers and infections.
With ProTcell™, Smart Immune has developed a groundbreaking clinical stage T-cell progenitor-based platform to rapidly and fully reset the patients’ T-cell compartment in order to fight blood cancers and severe infections.
Our ProTcell™ therapy shifts the risk: benefit ratio of allogenic T-cell medicine; significantly reducing adverse events observed in current allogenic practice, thus addressing a large unmet therapeutical need in patients.
The Immune T Cell system is the most efficient weapon for fighting life threatening cancers and infections
What if we could reset it without inducing adverse events ?
Bringing allo HSC curative power to patients in life threatening conditions without inducing adverse events
T Cell Progenitors: a new generation of allogenic T cell medicine enabling a reset of T cell immune system to fight cancers and infections
A rapid efficiency without inducing adverse events to improve significantly life expectancy and quality
Partnership set to develop fully-automated , miniaturized cell-culture bioreactors to produce HSC-derived cell-culture products at scale
Our latest news and updates
Smart Immune Announces Acceptance of Two Abstracts Covering Preclinical Research and Clinical Data at the American Society of Hematology
PARIS, France, Nov 05, 2021 – Data Presented at ASH Underscores the Potential of the Smart-Immune Platform That Can Generate ex-vivo T- cell progenitors and NK- Cells for the Treatment of Primary Immunodeficiencies, and Cancers.
Smart Immune Receives IRB Approval For Phase 1/2 Clinical Trial of Proprietary Allogeneic T-cell Product Smart-101 (ProTcell™) for AML and ALL.
PARIS, France, Oct 13, 2021 – Smart Immune SAS, a T cell medicine company utilizing its proprietary ex-vivo biomimetic “thymus in a dish” technology to develop allogeneic T-cell progenitors Smart101 (ProTcell™) for rapid immune reconstitution, announced today that the institutional review board (IRB) of the Memorial Sloan Kettering Cancer Center (MSK) has approved the commencement of the Company’s phase 1/2 clinical trial. MSK will start enrolling patients in November, 2021.
TNFα-supplemented DL-4 culture system supports first-in-clinic Smart Immune ProTcell™ technology for immuno-deficient patients fighting cancers and infections
Smart Immune’s unique ex-vivo biomimetic ProTcell™ ‘thymus in a dish’ platform technology, designed to generate specific human T-cell progenitor cells at scale with high purity, homogeneity, and yield, has been reinforced by data published in the peer-reviewed journal Cellular & Molecular Immunology.